HCC in disease context refers to hepatocellular carcinoma, the most common primary liver cancer in adults. It frequently arises in the setting of chronic liver disease and cirrhosis, especially with hepatitis B or C and metabolic/alcohol-related liver injury. Prognosis is strongly stage-dependent and often poor in advanced disease.
New research links gut microbiome composition to cancer immunotherapy outcomes. A 674-patient study showed gut bacteria predict melanoma recurrence with up to 94% accuracy, while other studies identified specific microbes influencing treatment response and resistance in melanoma and liver cancer.
An armored GPC3-directed CAR T-cell therapy showed manageable safety and antitumor activity in refractory HCC, with 44.4% objective responses and 14.2-month median overall survival in a first-in-human trial.
Biotech education expands with new Auburn grad programs, a 2+2 transfer pathway at Elizabethtown/Harford, a USDA K-12 plant biotech initiative at BTI, and a new lab at Baku Engineering University.
Studies highlight ferroptosis and cuproptosis in cancer therapy: a DDR1/VEGFR2 inhibitor reverses gastric cancer chemoresistance, GSH-responsive nanoparticles enhance HCC immunotherapy, and nutrient restriction boosts Sorafenib-induced ferroptosis.
New research links coffee to lower liver disease risk and sugary beverages to higher liver cancer risk. Two studies appear in Clinical Gastroenterology and Hepatology and JAMA Network Open.
Can-Fite will present late-stage pipeline at BIO 2026; GlobalData counts over 2,000 peptides in development with $91.38bn 2025 sales; Arrowhead's RNAi pipeline has two Phase 3 programs.
AI-driven studies are advancing cancer drug discovery across multiple tumor types, including a pan-cancer proposal of AMG-900, a novel gp130 inhibitor for colorectal cancer, and the Kinic Index for hepatocellular carcinoma. Machine learning is also being integrated into computational platforms like Isomorphic Labs' IsoDDE to model molecular interactions.
A two-step FIB-4 plus VCTE approach effectively stratifies liver fibrosis and liver-related event risk in type 2 diabetes with MASLD. Prevalence of MASLD was 71.3% and significant fibrosis 21.1% in older outpatients.
New studies present SPARK, an AI framework for tumor analysis, a Cell review of liver cancer hallmarks and treatments, and a call for more research into lung cancer in never-smokers, which was the fifth most common cause of cancer death in 2020.
Tempest Therapeutics reported 2025 financial results showing $7.7 million in cash and highlighted clinical progress including 100% complete response rate in TPST-2003 CAR-T trial and multiple FDA designations for amezalpat in hepatocellular carcinoma. The company completed strategic CAR-T asset acquisition and plans Phase 2b registrational study for its lead program in 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07775716 |
Accumulation of Lipid Droplets as an Underlying Cause of the Progression of Fatty Liver Disease to Liver Cancer |
ACTIVE_NOT_RECRUITING | NA |
| NCT07722741 |
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC |
RECRUITING | PHASE2 |
| NCT07589244 |
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC |
RECRUITING | PHASE2/PHASE3 |
| NCT07379489 |
Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma |
NOT_YET_RECRUITING | |
| NCT07353333 |
Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3 |
NOT_YET_RECRUITING | NA |
| NCT07352007 |
Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular |
NOT_YET_RECRUITING | PHASE2 |
| NCT07350824 |
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC |
NOT_YET_RECRUITING | NA |
| NCT07350070 |
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension |
NOT_YET_RECRUITING | PHASE2 |
| NCT07340502 |
TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma |
NOT_YET_RECRUITING | |
| NCT07334483 |
A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC |
RECRUITING | PHASE2 |
